Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer

BACKGROUND: In metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted therapies (ARATs) abiraterone, apalutamide, or enzalutamide to androgen deprivation therapy (ADT). However, the optimal treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbier, Michaela C., Tomonaga, Yuki, Menges, Dominik, Yebyo, Henock G., Haile, Sarah R., Puhan, Milo A., Schwenkglenks, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632884/
https://www.ncbi.nlm.nih.gov/pubmed/36327294
http://dx.doi.org/10.1371/journal.pone.0277282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632884/
https://www.ncbi.nlm.nih.gov/pubmed/36327294
http://dx.doi.org/10.1371/journal.pone.0277282

Ejemplares similares